Related Experiment Videos
Insights
A pediatric case of ulcerative colitis complicated by toxic megacolon was successfully managed. Treatment involved prednisone and salicylazosulfapyridine, with careful monitoring leading to resolution and long-term improvement.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease Research
- Colorectal Surgery
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Toxic megacolon is a rare but serious complication of UC, particularly in infants.
- Management of pediatric UC with toxic megacolon presents unique challenges.
Observation:
- A 12-week-old infant with UC presented with toxic megacolon.
- Initial response to prednisone for diarrhea and rectal bleeding was observed.
- Recurrence of toxic dilatation occurred despite salicylazosulfapyridine treatment and prednisone withdrawal.
Findings:
- Close medical observation, prednisone readministration, and avoidance of abdominal exams led to toxic megacolon resolution.
- One-year follow-up showed improvement in UC, with only friable mucosa on sigmoidoscopy and improved barium enema findings.
- The patient remained asymptomatic on daily salicylazosulfapyridine with normal growth and development.
Implications:
- This case highlights the potential for successful medical management of toxic megacolon in infants with UC.
- It underscores the importance of individualized treatment strategies and close monitoring in pediatric inflammatory bowel disease.
- The findings suggest a potential role for salicylazosulfapyridine in long-term maintenance therapy for UC in this age group.
Abstract:
A 12-week-old white male infant with ulcerative colitis and toxic megacolon is described. His diarrhea and rectal bleeding responded to prednisone. He subsequently developed toxic dilatation of the transverse colon while on salicylazosulfapyridine and one week after discontinuation of prednisone. His toxic megacolon disappeared during close medical observation, readministration of prednisone, and avoidance of repeated abdominal examinations. One year later sigmoidoscopy showed only friable mucosa and the barium enema showed the presence of ulcerative colitis but with improvement from the initial study. Currently he is taking 375 mg of salicylazosulfapyridine daily. Growth and development are normal and he is asymptomatic.